Head and neck cancers

Recommended treatments for these cancers commonly cause CINV6

  • Highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens including agents such as
    • Cisplatin
    • Carboplatin
    • Paclitaxel
    • 5-FU
  • Multiday regimens resulting in overlapping periods of acute and delayed CINV
  • Chemotherapy in combination with radiation therapy, potentiating CINV effects

Specific issues may prevent the ability to protect against CINV

Oral mucositis and dry mouth
  • Most patients undergoing radiation therapy for head and neck cancers will develop mucositis7
  • 5-FU is highly stomatotoxic8
  • Radiation therapy, which is commonly used in combination with chemotherapy, increases the chances of developing mucositis8

Inability to take pills
  • Patients may experience difficulty swallowing or a loss of appetite due to the tumor location, treatment types, or previous surgery
  • Patients may experience swelling of the mouth and gums

Peripheral neuropathy
  • Peripheral neuropathy, limiting a patient’s ability to take pills, is a common side effect of paclitaxel therapy9

A high incidence of CINV
  • Cisplatin carries a greater than 90% risk of developing CINV10
    • There is greater than
      65% risk of developing
      delayed CINV with cisplatin10

SANCUSO is the right choice

  • Successfully studied in head and neck cancers in a phase III trial2
  • Helps to prevent CINV caused by MEC and HEC regimens1
  • Provides continuous coverage with one application, so adherence to treatment is not an issue1
  • Alternative to taking pills to achieve CINV protection